Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 58
Filter
Add more filters










Publication year range
2.
Toxicol Sci ; 53(1): 33-9, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10653518

ABSTRACT

Twenty-one monkeys (cynomolgus, rhesus, African green) were fed cyclamate (100 mg/kg and 500 mg/kg) in the diet five times per week from a few days after birth and continuing for up to 24 years. Malignant tumors were diagnosed in three 24-year-old cyclamate monkeys; these were metastatic colon carcinoma (rhesus; 500 mg/kg), metastatic hepatocellular carcinoma (cynomolgus; 500 mg/kg), and a small, well differentiated adenocarcinoma of the prostate (cynomolgus; 100 mg/kg). Benign tumors were found at necropsy in three females; these were adenoma of the thyroid gland (rhesus; 100 mg/kg) and two cases of leiomyoma of the uterus (rhesus; 100 mg/kg and 500 mg/kg). No tumors were detected in an age-matched control group of 16 monkeys. Examination of the testes revealed complete testicular atrophy in one of the old cyclamate monkeys, and focal germ cell aplasia (Sertoli-only tubules) in two other cyclamate monkeys. Focal spermatogenic interruption (maturation arrest) at various germ cell levels mixed with normal spermatogenesis was observed in both the cyclamate-treated and the control monkeys, all of which were over 20 years old. Measurements of terminal cyclohexylamine concentrations showed that three of the males dosed with cyclamate at 500 mg/kg were high converters, with plasma concentrations comparable to the levels that produce testicular atrophy in rats. However, only one of the three high converters showed histologic evidence of irregular spermatogenesis. The overall conclusion is that the testicular abnormalities and the sporadic cases of different malignancies found after more than 20 years of dosing do not provide clear evidence of a toxic or carcinogenic effect of sodium cyclamate in monkeys.


Subject(s)
Carcinogens/toxicity , Cyclamates/toxicity , Animals , Animals, Newborn , Atrophy/chemically induced , Atrophy/pathology , Carcinogenicity Tests , Chlorocebus aethiops , Cyclohexylamines/blood , Female , Longitudinal Studies , Macaca fascicularis , Macaca mulatta , Male , Neoplasms, Experimental/etiology , Rats , Testis/drug effects , Testis/pathology
3.
J Cancer Res Clin Oncol ; 125(3-4): 219-25, 1999.
Article in English | MEDLINE | ID: mdl-10235477

ABSTRACT

Because of reports on tumorigenic activity in different animal species exposed to DDT a decision was made in 1969 to evaluate the long-term effects of DDT on 24 cynomolgus and rhesus monkeys. DDT (20 mg/kg) was given in the diet for 130 months, followed by an observation period that ended in 1994. The two cases of malignant tumor detected in the DDT group included a metastatic hepatocellular carcinoma in a 233-month-old male and a well-differentiated adenocarcinoma of the prostate in a 212-month-old monkey. Benign tumors detected in the DDT group included three cases of leiomyoma, two of which were uterine and one, esophageal. No tumor was detected in the control group of 17 monkeys. Fatty changes in the liver were observed in 52.9% of the DDT group and 29.4% of the control group. More specific signs of hepatotoxicity were documented microscopically in seven DDT monkeys. Severe tremors and histological evidence of CNS and spinal cord abnormalities were observed in six DDT monkeys. The present findings show clear evidence of hepatic and CNS toxicity following long-term DDT administration to cynomolgus and rhesus monkeys. However, the two cases involving malignant tumors of different types are inconclusive with respect to a carcinogenic effect of DDT in nonhuman primates.


Subject(s)
Carcinogens/toxicity , DDT/toxicity , Insecticides/toxicity , Neoplasms, Experimental/chemically induced , Adenocarcinoma/chemically induced , Administration, Oral , Animals , DDT/blood , Female , Insecticides/blood , Leiomyoma/chemically induced , Liver/drug effects , Liver Neoplasms, Experimental/chemically induced , Macaca fascicularis , Macaca mulatta , Male , Mammary Glands, Animal/drug effects , Ovary/drug effects , Prostatic Neoplasms/chemically induced , Time Factors , Uterine Neoplasms/chemically induced , Uterus/drug effects
4.
J Natl Cancer Inst ; 90(1): 19-25, 1998 Jan 07.
Article in English | MEDLINE | ID: mdl-9428778

ABSTRACT

BACKGROUND: It was observed in the early 1970s that saccharin produced bladder cancer in rats. However, it has been unclear whether sodium saccharin when consumed by humans poses a substantial carcinogenic hazard. Numerous epidemiologic studies have not shown any evidence of increased urothelial proliferation associated with ingestion of sodium saccharin. PURPOSE: Our purpose was to determine the effects of long-term feeding of sodium saccharin to three species of nonhuman primates. METHODS: Twenty monkeys of three species (six African green, seven rhesus, six cynomolgus, and one hybrid [of rhesus male and cynomolgus female parentage]) were treated with sodium saccharin (25 mg in the diet/kg body weight daily for 5 days a week) beginning within 24 hours after birth and continuing for up to 24 years. Sixteen monkeys (seven rhesus and nine cynomolgus) served as controls. During their last 2 years of life, urine was collected from selected treated and control animals and evaluated for various urinary chemistries and for the presence of calculi, microcrystalluria, and precipitate. Urinary bladders were examined by light microscopy and by scanning electron microscopy. RESULTS: Sodium saccharin treatment had no effect on the urine or urothelium in any of these monkeys. There was no evidence of increased urothelial cell proliferation, and there was no evidence of formation of solid material in the urine. CONCLUSION: Although the dose of sodium saccharin administered to these monkeys was only five to 10 times the allowable daily intake for humans, the results provide additional evidence that sodium saccharin is without a carcinogenic effect on the primate urinary tract.


Subject(s)
Carcinogens/toxicity , Saccharin/toxicity , Urinary Bladder/drug effects , Urine/chemistry , Urothelium/drug effects , Animals , Carcinogens/administration & dosage , Cell Division/drug effects , Female , Haplorhini , Male , Microscopy, Electron, Scanning , Saccharin/administration & dosage , Ultrasonography , Urinary Bladder/diagnostic imaging
7.
Epidemiology ; 6(5): 544-6, 1995 Sep.
Article in English | MEDLINE | ID: mdl-8562633

ABSTRACT

We conducted a nested case-control study with 1,925 women enrolled in a polybrominated biphenyl (PBB) registry to examine the association between breast cancer and serum PBBs. Twenty women who developed breast cancer were matched to 290 control subjects on sex, race, and age. Women with serum PBB levels of 2.0-3.0 parts per billion (ppb) [odds ratio (OR) = 3.5; 95% confidence interval (CI) = 0.9-13] or 4.0 ppb or greater (OR = 3.1; 95% CI = 0.8-12) had a higher estimated risk for breast cancer than women with less than 2.0 ppb. The odds ratios were unchanged when available breast cancer risk factors were included in the analysis.


Subject(s)
Breast Neoplasms/epidemiology , Food Contamination , Polybrominated Biphenyls/adverse effects , Breast Neoplasms/blood , Breast Neoplasms/chemically induced , Case-Control Studies , Cohort Studies , Female , Humans , Meat , Michigan/epidemiology , Odds Ratio , Polybrominated Biphenyls/blood , Registries , Risk Factors
8.
J Immunol ; 139(9): 3041-9, 1987 Nov 01.
Article in English | MEDLINE | ID: mdl-3499463

ABSTRACT

Quantitative pharmacokinetic measurements of uptake and metabolism for two murine immunoglobulin G1 (IgG1) monoclonal antibodies (anti-Lyb8.2, MOPC-21) and their F(ab')2 and Fab' fragments were obtained following i.v. administration into C57BL/6 mice. Anti-Lyb8.2 antibody, reactive with the allelic Lyb8.2 murine B cell antigen, was labeled with 125I, and MOPC-21, an antibody with no known target antigen, was labeled with 131I. The two IgG or their fragments were co-injected, and all major organs were analyzed. Specific uptake of anti-Lyb8.2 IgG, F(ab')2, and Fab' was observed in the spleen with maximum peak values occurring at 1 to 2 hr. For MOPC-21, blood and organ kinetics was indicative of a nontargeted IgG molecule. The kidneys showed significant and rapid uptake of anti-Lyb8.2 and MOPC-21 Fab' fragments. This uptake by kidneys attenuated the maximum peak values of anti-Lyb8.2 Fab' in spleen. Multiexponential data fitting provided mean residence times (MRT) for each organ. The MRT for anti-Lyb8.2 in all organs were greater than those for its F(ab')2 and Fab' fragments. Only the kidneys showed greater MRT for Fab' than for F(ab')2. Blood, spleen, kidneys, and carcass exhibited substantial differences across fragments. When total body MRT for each fragment was compared with that of the respective parent IgG molecule, a progressive decline was observed. For MOPC-21, the decrease in total body MRT for F(ab')2 demonstrates the influence of the Fc portion of the molecule on IgG1 metabolism. This organ-by-organ data set may be pertinent to other monoclonal antibodies and their fragments and should help in optimizing delivery of these molecules to specific sites in vivo for immunologic and clinical purposes.


Subject(s)
Antigens, Ly/immunology , B-Lymphocytes/immunology , Immunoglobulin Fab Fragments/pharmacokinetics , Immunoglobulin G/pharmacology , Isoantibodies/metabolism , Animals , Antibodies, Monoclonal , Immunoglobulin Fab Fragments/administration & dosage , Immunoglobulin G/administration & dosage , Injections, Intravenous , Metabolic Clearance Rate , Mice , Tissue Distribution
9.
Cancer Res ; 47(8): 2073-6, 1987 Apr 15.
Article in English | MEDLINE | ID: mdl-3828997

ABSTRACT

The tissue localization of a radiolabeled monoclonal antibody directed against a mouse Class I major histocompatibility antigen has been determined in mice following i.v. and s.c. administration. When labeled antibody was given s.c., radioactivity rapidly accumulated in regional lymph nodes draining the injection site, allowing visualization of the nodes by gamma camera imaging within minutes of injection. At 2 h after s.c. injection, radioactivity in regional nodes was present largely as intact antibody, but considerable degradation of antibody present in nodes was noted by 12 h after injection. Since little of the radioactivity reached the blood stream, visualization of regional nodes was possible for long periods after dosing. In contrast, antibody given i.v. showed no significant accumulation in lymph nodes at any time after dosing.


Subject(s)
Antibodies, Monoclonal , Lymphatic System/metabolism , Animals , H-2 Antigens/analysis , H-2 Antigens/immunology , Iodine Radioisotopes , Lymph Nodes/metabolism , Lymphatic Metastasis , Mice , Mice, Inbred C57BL , Molecular Weight , Tissue Distribution
10.
Cancer Res ; 46(4 Pt 1): 1830-4, 1986 Apr.
Article in English | MEDLINE | ID: mdl-3948166

ABSTRACT

After interstitial injection in mice, antibody molecules enter local lymphatic vessels, flow with the lymph to regional lymph nodes, and bind to target antigens there. Compared with i.v. administration, delivery via the lymphatics provides a more efficient means for localizing antibody in lymph nodes. An IgG2a (36-7-5) directed against the murine class I major histocompatibility antigen H-2Kk has proved useful for studying the pharmacology of lymphatic delivery. The antibody specifically binds to most cells in Kk-positive strains of mice and to none in Kk-negative mice. At very low doses, most of the antibody remains at the injection site in Kk-positive animals. As the dose is progressively increased, most effective labeling occurs first in nodes proximal to the injection site and then in the next group of nodes along the lymphatic chain. At higher doses, antibody overflows the lymphatic system and enters the blood-stream via the thoracic duct and other lymphatic-venous connections. Once in the blood, antibody is rapidly cleared, apparently by binding to Kk-bearing cells. These findings indicate that the single-pass distribution of monoclonal antibodies in the lymphatics can be strongly dose dependent, a principle which may be of clinical significance in the improvement of immunolymphoscintigraphic imaging, especially with antibodies directed against normal and malignant lymphoid cells. Monoclonal antibodies directed against normal cell types in the lymph node may be useful for assessing the integrity of lymphatic chains by immunolymphoscintigraphy or, more speculatively, for altering the status of regional immune function. The results presented here indicate that a low or intermediate antibody dose may optimize the signal:noise ratio for imaging. In Kk-negative animals, the percentage of dose taken up in the major organs was essentially independent of the dose administered; there was no evidence for saturable sites of nonspecific binding. These findings provide background for attempts to use antitumor antibodies via the lymphatic route. Specific binding to target cells (and any cross-reaction with normal tissues) would presumably be superimposed on the nonspecific pharmacology of the antibody in vivo.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Lymphatic System/metabolism , Animals , Antibodies, Monoclonal/physiology , Dose-Response Relationship, Drug , H-2 Antigens/immunology , Iodine Radioisotopes , Lymph Nodes/metabolism , Lymphatic Metastasis , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Molecular Weight , Temperature
11.
Comp Biochem Physiol B ; 84(2): 143-4, 1986.
Article in English | MEDLINE | ID: mdl-3089678

ABSTRACT

The metabolic pathways giving rise to the urinary metabolites of S-carboxymethyl-L-cysteine have been identified for the rhesus, cynomologus, African green and marmoset species of monkey. The formation of a sulphoxide metabolite from the sulphide precursor is a reaction important in these species. The metabolic profile displayed by the marmoset was distinct from the three Old World species, with the rhesus and cynomologus being similar to man.


Subject(s)
Carbocysteine/metabolism , Cysteine/analogs & derivatives , Haplorhini/metabolism , Animals , Callitrichinae/metabolism , Chlorocebus aethiops/metabolism , Kinetics , Macaca fascicularis/metabolism , Macaca mulatta/metabolism , Male , Oxidation-Reduction , Species Specificity
14.
Cancer Treat Rep ; 68(1): 257-64, 1984 Jan.
Article in English | MEDLINE | ID: mdl-6692428

ABSTRACT

Monoclonal antitumor antibodies are being administered iv in a number of medical centers for diagnosis or therapy of human cancers. However, when the objective is to detect or to treat tumor in regional lymph nodes, sc injection may prove more effective. After sc injection, monoclonal antibodies enter local lymphatic capillaries, pass to the draining lymph nodes, and bind to target cells there. Antibody not bound in the first node group encountered passes to more distant nodes. If still not removed from the lymph flow, antibody passes into the bloodstream, principally through the thoracic duct. Initial studies of the lymphatic approach were done with antibodies directed against antigens on normal cell types in the mouse lymph node. The use of antibodies to normal cells made it possible to study the pharmacokinetics of delivery in a reproducible, quantitatively interpretable system. The pharmacologic models developed were then applied to the design of experiments on line 10 hepatocarcinoma of guinea pigs. As little as 2 mg of line 10 tumor could be identified by gamma camera imaging in regional nodes after injection of 125I-labeled antibody. The uptake was immunologically specific, and autoradiography showed localization exclusively within the metastatic tumor. When the aim is to diagnose or treat early tumor metastases in the nodes, the lymphatic route can be expected to provide higher sensitivity, lower background, lower systemic toxicity, and faster localization than the iv route. Perhaps most interesting, the lymphatic route minimizes exposure of antibody to cross-reactive antigen present on normal tissues elsewhere in the body. Antitumor antibodies rejected for iv use because they also bind to normal tissues may, therefore, be useful in the diagnosis and treatment of lymph node metastases.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Antibodies, Neoplasm/administration & dosage , Liver Neoplasms, Experimental/therapy , Lymph Nodes/immunology , Neoplasms/therapy , Animals , Guinea Pigs , Humans , Immunotherapy , Liver Neoplasms, Experimental/immunology , Neoplasms/diagnosis
15.
Science ; 222(4622): 423-6, 1983 Oct 28.
Article in English | MEDLINE | ID: mdl-6623082

ABSTRACT

After subcutaneous injection, monoclonal antibodies directed against a tumor can enter local lymphatic vessels, pass to the draining lymph nodes, and bind to metastases there. Lymphatic delivery of antibody to early metastases is more efficient than intravenous administration, and the lymphatic route can be used to image smaller metastatic deposits. Perhaps more important, the lymphatic route minimizes binding of antibodies to circulating tumor antigens and to cross-reactive antigens present on normal tissues. Antibodies inappropriate for intravenous use because of binding to normal tissues may therefore be useful against lymph node metastases when injected subcutaneously or directly into lymphatic vessels.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Liver Neoplasms, Experimental/immunology , Lymphatic Metastasis/immunology , Animals , Guinea Pigs , Injections, Subcutaneous , Iodoproteins , Lymphatic Metastasis/diagnosis
16.
J Immunopharmacol ; 5(1-2): 65-75, 1983.
Article in English | MEDLINE | ID: mdl-6655251

ABSTRACT

Effects of maleic anhydride-divinyl ether (MVE-2) on lymph node and lung metastases were studied in rats transplanted with a syngeneic mammary adenocarcinoma. Subcutaneous treatment with MVE-2 was administered according to various schedules, with or without surgical removal of the primary tumor. A significant reduction in size and/or incidence of lymph node metastases was observed, although no effect on the primary tumor was noted. Histologic evidence of degeneration of metastatic tumor cells, which were surrounded by lymphocytes and a characteristic focal histiocytosis, was present in the regional lymph nodes. The number of lung metastases resulting from iv injection of tumor cells was also significantly reduced following iv injection of MVE-2.


Subject(s)
Mammary Neoplasms, Experimental/drug therapy , Neoplasm Metastasis/prevention & control , Polymers/therapeutic use , Pyran Copolymer/therapeutic use , Animals , Female , Lung Neoplasms/secondary , Lymph Nodes/pathology , Lymphatic Metastasis/prevention & control , Rats
17.
Am J Physiol ; 244(1): H89-96, 1983 Jan.
Article in English | MEDLINE | ID: mdl-6849409

ABSTRACT

Intact and thoracic duct-cannulated rats were dialyzed at various intraperitoneal pressures with 5% bovine serum albumin solutions containing 125I-fibrinogen or 51Cr-erythrocytes. Lymphatic transport rates were calculated from the mass of tracer passing into the plasma space as function of tracer concentration in the peritoneal fluid during dialysis periods ranging between 143 and 360 min. Peritoneal protein concentrations were constant over the duration of the experiments. The calculated lymph flow rate was independent of intraperitoneal pressure and in intact rats averaged 2.85 +/- 1.22 microliters/min for uptake of 125I-fibrinogen and 2.60 +/- 1.17 for uptake of 51Cr-erythrocytes. However, the observed fluid loss rates from the peritoneal cavity were sensitive to the intraperitoneal pressure and were 5 to 20 times the calculated lymph flow rate. Mass balance experiments in two rats dialyzed with 125I-fibrinogen indicated that a significant proportion (28%) of tracer leaving the peritoneal cavity is absorbed by the anterior muscle wall of the abdomen and is probably trapped there because of its large molecular weight. Results from 125I-fibrinogen and 51Cr-erythrocyte uptake experiments both indicated that only approximately 30% of the total lymphatic drainage of the peritoneal cavity passes through the thoracic duct in rats.


Subject(s)
Erythrocytes/metabolism , Fibrinogen/metabolism , Lymph/metabolism , Peritoneal Cavity/metabolism , Animals , Ascitic Fluid/metabolism , Biological Transport , Chromium Radioisotopes , Female , Iodine Radioisotopes , Kinetics , Peritoneal Dialysis , Pressure , Rats , Rats, Inbred Strains , Thoracic Duct/physiology
18.
Pharmacology ; 26(4): 230-40, 1983.
Article in English | MEDLINE | ID: mdl-6844398

ABSTRACT

Tissue distribution following subcutaneous injection of liposomes containing melphalan (MPL) was studied in rats using 14C-MPL and 3H-phosphatidylcholine. Two types of liposomes, prepared by either a brief or a prolonged sonication, were compared. Brief sonication formed large liposomes of various sizes, while liposomes obtained after a prolonged sonication were small and relatively uniform in size (34 nm in mean diameter). Subcutaneous injection of small liposomes produced a strikingly high and sustained concentration of MPL equivalents in regional lymph nodes. In contrast, most liposomes prepared by a brief sonication appeared to remain at the injection site, and there was only a slight increase in the lymph node concentration of MPL equivalents over the plasma level during the 24-hour experiments.


Subject(s)
Liposomes/administration & dosage , Lymph Nodes/metabolism , Melphalan/metabolism , Animals , Female , Lymphatic Metastasis , Melphalan/administration & dosage , Neoplasms/drug therapy , Rats , Rats, Inbred F344 , Sonication , Tissue Distribution
20.
Science ; 218(4579): 1334-7, 1982 Dec 24.
Article in English | MEDLINE | ID: mdl-7146917

ABSTRACT

Monoclonal antibodies subcutaneously injected into mice track to regional lymph nodes and specifically label target cells there. The lymphatic route of administration can be expected to provide much higher sensitivity, higher target-to-background ratio, faster localization, and lower toxicity than the intravenous route when the aim is to diagnose or treat tumor metastases or lymphoma in the lymph nodes.


Subject(s)
Antibodies, Monoclonal , Lymph Nodes/cytology , Neoplasm Metastasis/diagnosis , Animals , Antibodies, Monoclonal/administration & dosage , Injections, Subcutaneous , Major Histocompatibility Complex , Methods , Mice , Mice, Inbred C57BL
SELECTION OF CITATIONS
SEARCH DETAIL
...